drugset
drugset / Trial / NCT05063877

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

NCT05063877 ↗

Phase 2 Unknown 43 enrolled Equilibre Biopharmaceuticals B.V.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a double-blind, placebo controlled, randomized study of dose-ranging safety, tolerability, exploratory efficacy of adjunctive EQU-001 for seizures using the continuous reassessment method in patients diagnosed with epilepsy.

Timeline

Start
2021-08-31
Primary completion
2022-10-11
Completion
2023-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject EQU-001 Unknown 10 mg Oral
Subject EQU-001 Unknown 20 mg Oral
Subject EQU-001 Unknown 40 mg Oral
Subject EQU-001 Unknown 60 mg Oral
Subject EQU-001 Unknown 80 mg Oral

Indications

epilepsy